Skip to main content

Table 4 Recurrence-free, distant metastasis-free, and melanoma-specific survival rates in the population of patients receiving a sentinel lymph node biopsy

From: Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients

 

RFS (# events, 95% CI)

DMFS (# events, 95% CI)

MSS (# events, 95% CI)

Class 1 (n = 159)

79% (37, 72–85%)

87% (24, 82–93%)

97% (7, 94–100%)

Class 2 (n = 178)

51% (89, 44–59%)

59% (74, 51–67%)

78% (35, 71–85%)

SLN- (n = 180)

79% (43, 73–85%)

85% (32, 80–91%)

95% (9, 92–99%)

SLN+ (n = 157)

47% (82, 39–56%)

55% (66, 47–65%)

75% (33, 68–84%)

Class 1/SLN- (n = 103)

87% (15, 81–94%)

93% (9, 88–98%)

98% (2, 95–100%)

Class 1/SLN+ (n = 56)

61% (22, 49–76%)

74% (15, 63–88%)

93% (5, 86–100%)

Class 2/SLN- (n = 77)

67% (28, 57–79%)

75% (23, 66–85%)

92% (7, 85–98%)

Class 2/SLN+ (n = 101)

37% (60, 28–49%)

44% (51, 34–56%)

63% (28, 52–76%)

  1. CI confidence interval, DMFS distant metastasis-free survival, GEP gene expression profile, RFS recurrence-free survival, SLN sentinel lymph node, MSS melanoma-specific survival